Expiration date: 08/2025
Release form
Solution for injection
Packaging
10 pcs
Pharmacological action
Mesaton - alpha-adrenomimetic, vasoconstrictor, vasoconstrictor. Stimulates postsynaptic alpha-adrenergic receptors.
It is biotransformed in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). It is excreted by the kidneys in the form of metabolites. The action begins immediately after administration and continues for 20 (after intravenous administration) — 50 minutes (with subcutaneous injection) - 1-2 hours (after intravenous injection).
The heart rate decreases, the shock output increases, the sBP and dBP increase, the pulse reflexively decreases. OPSS increases. It stimulates the brain and spinal cord. Reduces blood flow — renal, cutaneous, in the abdominal organs and extremities, increases — coronary. It narrows the pulmonary vessels and increases the pressure in the pulmonary artery. As a vasoconstrictor, it has an anticongestive effect: it reduces swelling and hyperemia of the nasal mucosa, the severity of exudative manifestations, restores free breathing, lowers pressure in the paranasal cavities and in the middle ear. Causes dilation of the pupils, normalizes intraocular pressure in open-angle forms of glaucoma.
Indications
Subdural and inhalation anesthesia (to maintain an adequate level of blood pressure and prolongation of subdural anesthesia), local anesthesia (as a vasoconstrictor), acute circulatory failure, anaphylaxis, neurogenic shock, hypotension, including orthostatic, paroxysmal supraventricular tachycardia, reperfusion arrhythmias (Berzold — Yarisch reflex), priapism, secretory prerenal anuria, iritis, iridocyclitis.
Contraindications
Hypersensitivity, severe arterial hypertension, ventricular tachycardia, tendency to angiospasm, bradycardia, shock in myocardial infarction, decompensated heart failure, conduction disorders, severe atherosclerosis, severe forms of CHD, cerebral artery damage, arterial hypertension, acute pancreatitis and hepatitis, hyperthyroidism, peripheral and mesenteric artery thrombosis, hypertrophy prostate cancer, pregnancy, children (up to 15 years) and the elderly.
Method of administration and dosage
P / c, i / m, i/v jet slowly or infusion (at a rate of 60-120 ml/h). For intravenous injection, 10 mg is dissolved in 9 ml of water, for intravenous infusion, 10 mg is added to 500 ml of 0.9% sodium chloride solution or 5% glucose. Moderate hypotension — n / a 2-5 mg (1-10 mg), intravenous 0.2 mg (0, 1-0. 5 mg), the interval between injections-at least 10-15 minutes. Severe hypotension and shock-IV drip, the initial infusion rate is 0, 1-0. 18 mg / min, as the blood pressure stabilizes, the rate is reduced to 0, 04-0. 06 mg/min. Paroxysmal supraventricular tachycardia-in / in a jet, the initial dose is no more than 0.5 mg for 20-30 seconds, the dose is gradually increased by 0, 1-0, 2 mg, 1 mg no more. Before subdural anesthesia (for the prevention of arterial hypotension), 2-3 mg/m or 0.2 mg (maximum — up to 0.5 mg) is administered intravenously 3-4 minutes before the procedure. For prolongation of subdural anesthesia — 2-5 mg is added to the anesthetic solution. As a vasoconstrictor for regional analgesia, it is added to the anesthetic solution at the rate of 1 mg per 20 ml.
